Quarterly Report III 23/24

September 2023 – May 2024, Diamyd Medical AB (publ), Fiscal year 2023/2024Comments by CEO Ulf Hannelius Dear Shareholders, The recent share issue, including warrants, has strengthened our financial position at this pivotal time. This capital infusion supports our efforts in advancing clinical programs and scaling operations. Importantly, this was achieved with minimal dilution for existing shareholders and at a cost substantially below prevailing market rates. With the cash position end of May of approximately 162 MSEK and a warrant structure including warrants in September this year